© MD Anderson Cancer Center
Protocols
Biospecimen Banking and Biomarker Validation for Lung Cancer Early Detection in Cohort Receiving Low Dose Helical Computed Tomography Screening
Silvia Hodge, RN, BSN, CCRP
Clinical Research Quality Specialist
E-mail: Shodge@mdanderson.org
Phone: 713-563-4525
Charlene Upshaw, BS
Research Quality Coordinator
E-mail: Ceupshaw@mdanderson.org
Phone: 713-563-0512
Phase II Randomized Study of Lower Doses of Decitabine (DAC; 20 mg/m2 IV daily for 3 days every month) versus Azacitidine (AZA; 75 mg/m2 SC/IV daily for 3 days every month) versus Azacitidine (AZA; 75 mg/m2 SC/IV daily for 5 days every month) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Dependent versus Best Supportive Care (BSC) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Independent
Patricia Boone, RN
Senior Clinical Research Quality Specialist
E-mail: Paboone@mdanderson.org
Phone: 713-792-6696
Darrell Trumper
Research Quality Coordinator
E-mail: Dltrumper@mdanderson.org
Phone: 713-745-8699
TEXAS HEPATOCELLULAR CARCINOMA CONSORTIUM
Mary Jo T. Necesito-Reyes, RN, BSN
Senior Clinical Research Quality Specialist
E-mail: Mnecesito@mdanderson.org
Phone:
Darrell Trumper
Research Quality Coordinator
E-mail: Dltrumper@mdanderson.org
Phone: 713-745-8699
Phase II study of the levonorgestrel intrauterine device alone or in combination with the mTORC1 inhibitor, everolimus, for the treatment of complex atypical hyperplasia and stage Ia grade 1 endometrial cancer
Patricia Boone, RN
Senior Clinical Research Quality Specialist
E-mail: Paboone@mdanderson.org
Phone: 713-792-6696
Charlene Upshaw, BS
Research Quality Coordinator
E-mail: Ceupshaw@mdanderson.org
Phone: 713-563-0512
A Phase II Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel in Advanced Biliary Cancers
Mary Jo T. Necesito-Reyes, RN, BSN
Senior Clinical Research Quality Specialist
E-mail: Mnecesito@mdanderson.org
Phone:
Charlene Upshaw, BS
Research Quality Coordinator
E-mail: Ceupshaw@mdanderson.org
Phone: 713-563-0512
A Phase II Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel in Advanced Biliary Cancers
Silvia Hodge, RN, BSN, CCRP
Clinical Research Quality Specialist
E-mail: Shodge@mdanderson.org
Phone: 713-563-4525
Garret Bromley, BS
Research Quality Coordinator
E-mail: GSBromley@mdanderson.org
Phone: 832-750-1884
Neoadjuvant and Adjuvant Dabrafenib and Trametinib Compared to Upfront Surgery in Patients with Clinical Stage III or Oligometastatic Stage IV Melanoma (Combi-Neo)
Mary Jo T. Necesito-Reyes, RN, BSN
Senior Clinical Research Quality Specialist
E-mail: Mnecesito@mdanderson.org
Phone:
Charlene Upshaw, BS
Research Quality Coordinator
E-mail: Ceupshaw@mdanderson.org
Phone: 713-563-0512
Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies
Laura D. Henderson, RN, MSN
Supv. Clinical Research Quality
E-mail: Ldhenderson@mdanderson.org
Phone: 713-792-7317
Garret Bromley, BS
Research Quality Coordinator
E-mail: GSBromley@mdanderson.org
Phone: 832-750-1884
Inspire to Study Acute Recurrent and Chronic Pancreatitis in Children DNA substudy
Laura D. Henderson, RN, MSN
Supv. Clinical Research Quality
E-mail: Ldhenderson@mdanderson.org
Phone: 713-792-7317
Garret Bromley, BS
Research Quality Coordinator
E-mail: GSBromley@mdanderson.org
Phone: 832-750-1884
2013-0609
2014-0112 (MDS)
THCCC15-01
2014-0944 (Gyn-Westin)
2014-0524 (GI-Biliary)
CPDPC16-01
2014-0409 (Melanoma)
CPDPC16-02
CPDPC16-03
© MD Anderson Cancer Center